instruction
stringclasses 1
value | input
stringlengths 17
568
| output
stringlengths 1
80
|
|---|---|---|
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia. | Bicytopenia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine. | Myelosuppression |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | These findings suggest that bicytopenia in this patient was caused by D-Pen and may be due to different sensitivities in the hematopoietic lineage. | Bicytopenia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis. | Agranulocytosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case. | Tetany |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda. | Tetany |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Described here are 2 patients who developed thrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug gemcitabine. | Thrombotic microangiopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. | Renal failure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab. | B-cell lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The relationship between infliximab treatment and lymphoma in Crohn's disease. | Lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab. | Hodgkin's disease |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab. | B-cell lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia. | Lymphoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Of the four patients who responded to HU with an increase in total Hb, all reported symptomatic improvement and three have not required further transfusions. | Hodgkin's disease |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Sodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite increasing Hb F levels. | Haemoglobin increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We conclude that low-dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions. | Haemoglobin increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB. | Haemoglobin increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital. | Delirium |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | After abstinence from oolong tea his delirium resolved. | Delirium |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions. | Delirium |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages. | Rhabdomyolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir. | Angiolipoma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Elevated serum triglycerides with clozapine resolved with risperidone in four patients. | Blood triglycerides increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In two patients clozapine was reinstated after risperidone was discontinued; serum triglyceride levels increased. | Blood triglycerides increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients. | Blood triglycerides increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. | Hypotension |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | To our knowledge, this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population. | Hypotension |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11-year-old girl. | Hypotension |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine. | Rippling muscle disease |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A diagnosis of masked theophylline poisoning should be considered in similar situations involving a rapid decrease of insulin requirements. | Poisoning |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Salicylate intoxication was excluded, and theophylline was finally incriminated. | Poisoning |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Theophylline intoxication mimicking diabetic ketoacidosis in a child. | Poisoning |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This compound, used by adults in the child's home, had caused accidental theophylline poisoning, mimicking diabetic ketoacidosis. | Poisoning |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. | Encephalopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Ten to 15% of patients treated with ifosfamide develop an encephalopathy. | Encephalopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy. | Encephalopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding--successful thrombolysis under heparin therapy. | Portal vein Thrombosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report on a 14-year-old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII. | Portal vein Thrombosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 60-year-old woman with diabetes mellitus (type 2) developed an acute icteric hepatitis-like illness 6 weeks after the initiation of gliclazide therapy. | Hepatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Gliclazide-induced acute hepatitis. | Hepatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In conclusion, this case strongly suggests that gliclazide can induce acute icteric liver necro-inflammation which may be misdiagnosed clinically as acute viral hepatitis. | Hepatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites. | Hepatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe the case of acute hepatitis induced by gliclazide, a second generation sulfonylurea. | Hepatitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Caution is, therefore, needed to prevent undesired accumulation of TCA that may lead to protracted Cushing's syndrome. | Cushing's syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Cushing's syndrome persisted more than 6 months while TCA concentrations remained detectable for at least 80 days. | Cushing's syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The presented patient was treated with 200 mg TCA and developed Cushing's syndrome 6 weeks later (cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms/l). | Cushing's syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced. | Pulmonary function test decreased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin. | Bronchiolitis obliterans organising pneumonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury. | HepatitisOrganising pneumonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The spectrum of nitrofurantoin lung injury continues to widen. | Pulmonary radiation injury |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin. | Respiratory disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We suggest that the previous classification of nitrofurantoin induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged. | Pulmonary radiation injury |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha. | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases. | Acute erythroid leukemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy. | Neoplasm malignant |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent. | Scleroderma-like reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This is the first report of UFT-induced scleroderma-like reaction. | Scleroderma |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of a scleroderma-like reaction induced by long-term administration of UFT. | Scleroderma-like reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Central nervous system manifestations of an ibuprofen overdose reversed by naloxone. | Central nervous system manifestations |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation. | Dizziness |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone. | Depressed level of consciousness |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. | Acute Respiratory failure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported. | Hypersensitivity Pneumonitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome, a rare congenital disorder. | Pneumonitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature. | Superior sagittal sinus Thrombosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase. | Seizure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report on a young adolescent with benign intracranial hypertension which we attribute to the use of minocycline for acne. | Idiopathic intracranial hypertension |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B. | Polyarteritis nodosa |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose methotrexate therapy might have promoted the development of lung cancer. | Lung neoplasm malignant |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine-induced refractory coronary vasospasm. | Arteriospasm coronary |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable. | Liver injury |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury. | Hepatic failure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Troglitazone-induced fulminant hepatic failure. | Acute hepatic failure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities. | Lung disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis. | Pulmonary fibrosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The medical examiner's report indicated death caused by fluoxetine toxicity. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism. | Death |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Spinal cord infarction during use of zolmitriptan: a case report. | Spinal cord infarction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan. | Spinal cord infarction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use. | Renal failure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide. | Foetal Renal impairment |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated. | Acute myeloid leukaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause? | Leukaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose. | Acute myeloid leukaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | BACKGROUND: Cyanamide, an aversive agent widely used in Japan, is known to induce various degrees of hepatic lesion with ground-glass inclusion bodies. | Hepatic lesion |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Case 2: A 43-year-old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue. | Fatigue |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment. | Fatigue |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases. | Transaminases increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes. | Hepatic fibrosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases. | Hepatic function abnormal |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver. | Inflammation |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction. | Hypersensitivity |